1st International Workshop on NASH Biomarkers
Event Date: April 29 - 30, 2016
Event Location: Westin Alexandria Hotel, Washington DC
Diapharma is proud to sponsor the 1st International Workshop on NASH Biomarkers to be held in Washington DC, USA on 29-30 April 2016.
This abstract-driven workshop will provide a much-needed forum for presentation and in-depth discussion of the latest research results on biomarkers for NASH. The nature of the program will be interactive, stimulating international and cross-disciplinary interchange, in-depth discussion and debate. The program is initiated by an expert steering committee in order to reach consensus, integrate efforts, develop strategies and advance this important field of research.
The workshop is endorsed by the The International Association for the Study of the Liver (IASL).
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America, but the incidence is also increasing outside North America. It is a growing contributor to the burden of CLD requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which however may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver-related mortality.
There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. In particular methods to identify the subjects and the validation of endpoints that reflect meaningful changes in health status in this population are needed.